Terns Pharmaceuticals, Inc.
TERN
$6.53
$0.233.65%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -14.22% | -13.43% | -18.69% | -21.28% | 53.47% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -2.33% | 0.00% | -0.67% | 4.88% | 36.24% |
| Operating Income | 2.33% | 0.00% | 0.67% | -4.88% | -36.24% |
| Income Before Tax | 4.33% | 0.71% | 1.53% | -3.90% | -33.56% |
| Income Tax Expenses | -4.15% | -9.06% | 8.79% | -47.05% | -42.76% |
| Earnings from Continuing Operations | 4.33% | 0.73% | 1.50% | -3.60% | -33.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 4.33% | 0.73% | 1.50% | -3.60% | -33.07% |
| EBIT | 2.33% | 0.00% | 0.67% | -4.88% | -36.24% |
| EBITDA | 2.25% | -0.01% | 0.70% | -4.88% | -36.45% |
| EPS Basic | 20.36% | 13.56% | 10.99% | 6.81% | -2.12% |
| Normalized Basic EPS | 20.36% | 13.53% | 11.02% | 6.47% | -2.48% |
| EPS Diluted | 20.36% | 13.56% | 10.99% | 6.81% | -2.12% |
| Normalized Diluted EPS | 20.36% | 13.53% | 11.02% | 6.47% | -2.48% |
| Average Basic Shares Outstanding | 20.29% | 15.66% | 11.55% | 11.83% | 24.91% |
| Average Diluted Shares Outstanding | 20.29% | 15.66% | 11.55% | 11.83% | 24.91% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |